Refractory Plasma Cell Myeloma

Showing 26 - 50 of 80

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Adavosertib)

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Jun 28, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jun 14, 2022

Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (biological, drug, other)

Recruiting
  • Plasma Cell Myeloma
  • +2 more
  • Belantamab Mafodotin
  • +4 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 10, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 3, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Chemosensitivity Assay,

Terminated
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 6, 2022

Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma Trial in United States (ixazomib citrate, dexamethasone,

Active, not recruiting
  • Refractory Plasma Cell Myeloma
  • Recurrent Plasma Cell Myeloma
  • ixazomib citrate
  • +2 more
  • Scottsdale, Arizona
  • +4 more
Mar 28, 2022

Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in San Francisco (Pembrolizumab)

Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
Mar 23, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Ibrutinib, Laboratory

Suspended
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
    Mayo Clinic in Florida
Mar 22, 2022

Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia Trial in Duarte (drug,

Active, not recruiting
  • Autologous Hematopoietic Stem Cell Transplant Recipient
  • +4 more
  • Duarte, California
    City of Hope
Mar 17, 2022

ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma Trial in Atlanta

Active, not recruiting
  • ISS Stage I Plasma Cell Myeloma
  • +4 more
  • Pembrolizumab
  • Radiation Therapy
  • Atlanta, Georgia
    Emory University/Winship Cancer Institute
Mar 2, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological

Completed
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +3 more
  • Calgary, Alberta, Canada
  • +4 more
Feb 10, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Taselisib)

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Feb 4, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Crizotinib)

Active, not recruiting
  • Advanced Lymphoma
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Feb 4, 2022

Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia Trial in

Recruiting
  • Myelodysplastic Syndrome
  • +16 more
  • Computed Tomography
  • +6 more
  • Scottsdale, Arizona
  • +2 more
Feb 3, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Dexamethasone, Leflunomide, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Duarte, California
    City of Hope Medical Center
Jan 10, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 30, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Laboratory Biomarker Analysis, Lenalidomide,

Completed
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic
Dec 1, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (CS1-CAR T Therapy, Cyclophosphamide, Fludarabine)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • CS1-CAR T Therapy
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Nov 15, 2021

Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Elotuzumab, Pomalidomide)

Suspended
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
    Mayo Clinic in Florida
Oct 18, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Laboratory Biomarker Analysis, Leflunomide,

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Laboratory Biomarker Analysis
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Oct 4, 2021

Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (drug,

Terminated
  • Multiple Myeloma-Light Chain Only
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2021

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (FGFR Inhibitor

Completed
  • Advanced Lymphoma
  • +5 more
  • FGFR Inhibitor AZD4547
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Jun 8, 2021

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Nivolumab)

Completed
  • Advanced Lymphoma
  • +5 more
  • Nivolumab
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Mar 15, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (Bendamustine Hydrochloride, Carfilzomib,

Completed
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Bendamustine Hydrochloride
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 7, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (Dexamethasone, Lenalidomide, Thalidomide)

Completed
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2020